Stifel initiated coverage on Roivant Sciences (ROIV) with a Buy rating and a $51.00 price target. The firm identifies a multi-asset opportunity within Roivant’s subsidiaries targeting specialty autoimmune and lung disease markets. Stifel expects these assets to drive significant long-term sales.
JPMorgan reiterated its Overweight rating on Roivant following a positive physician survey. The survey indicates a strong outlook for the launch of Lisraya, the company's recently approved drug for dermatomyositis.